Departamentos de Anestesiología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Marcoleta 367, 8330024 Santiago, Chile.
Br J Anaesth. 2012 Jun;108(6):979-83. doi: 10.1093/bja/aes097. Epub 2012 Apr 6.
I.V. lidocaine is increasingly used as an adjuvant during general anaesthesia. The aim of this study was to evaluate the effect of i.v. lidocaine in reducing propofol anaesthetic requirements during total i.v. anaesthesia (TIVA) maintenance and to evaluate its effect on early recovery from anaesthesia.
Forty adult patients undergoing elective laparoscopic cholecystectomy under TIVA were randomly allocated into the lidocaine group (administered 1.5 mg kg(-1) i.v. lidocaine over 5 min followed by 2 mg kg(-1) h(-1)) and the control group (administered an equal volume of saline). Propofol was administered using a target-controlled infusion to maintain the bispectral index values between 40 and 60. After surgery, all infusions were discontinued and the time to extubation was recorded. Serial arterial blood samples were drawn to assess drug plasma levels.
The maintenance dose of propofol was significantly lower in the lidocaine group [6.00 (0.97) mg kg(-1) h(-1)] vs the control group [7.25 (1.13) mg kg(-1) h(-1); P=0.01]. Propofol plasma levels measured at the end of the infusion were 3.71 (0.89) μg ml(-1) in the lidocaine group and 3.67 (1.28) μg ml(-1) in the control group (P=0.91). The median time to extubation was longer (11.0 min; range: 10.0-21.0) in the lidocaine group vs the control group (8.3 min; range: 5.5-12.5; P=0.02).
I.V. lidocaine reduces propofol requirements during the maintenance phase of TIVA, particularly during surgical stimulation. This sparing effect is associated with an increased time to extubation. Owing to its effect on early recovery from anaesthesia, i.v. lidocaine should be taken into account when used as a component of i.v. anaesthesia.
静脉利多卡因在全身麻醉中越来越多地被用作辅助药物。本研究旨在评估静脉利多卡因在减少全静脉麻醉(TIVA)维持期间丙泊酚麻醉需求方面的效果,并评估其对麻醉后早期恢复的影响。
40 名接受 TIVA 下择期腹腔镜胆囊切除术的成年患者随机分为利多卡因组(静脉注射 1.5mg/kg 利多卡因 5 分钟,然后以 2mg/kg/h 的速度输注)和对照组(输注等量生理盐水)。使用靶控输注维持脑电双频指数值在 40 到 60 之间,以输注丙泊酚。手术后,所有输注均停止,并记录拔管时间。抽取动脉血样以评估药物血浆水平。
利多卡因组丙泊酚维持剂量明显低于对照组[6.00(0.97)mg/kg/h]vs[7.25(1.13)mg/kg/h];P=0.01]。输注结束时测量的利多卡因组丙泊酚血浆水平为 3.71(0.89)μg/ml,对照组为 3.67(1.28)μg/ml(P=0.91)。利多卡因组拔管时间中位数较长(11.0 分钟;范围:10.0-21.0)vs 对照组(8.3 分钟;范围:5.5-12.5;P=0.02)。
静脉利多卡因可减少 TIVA 维持期间丙泊酚的需求,特别是在手术刺激期间。这种节省作用与拔管时间的延长有关。由于其对麻醉后早期恢复的影响,静脉利多卡因在作为静脉麻醉的组成部分时应予以考虑。